Abcam Wins Industry Awards from CiteAb
March 24 2021 - 7:49AM
Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life
science reagents and tools, announced that Dr Alejandra Solache,
SVP of Research & Development received the CiteAb award for
‘Significant Individual Impact’ and the Company was recognized as
‘Antibody Supplier Succeeding in Cardiovascular Research’.
On receiving her award, Dr Alejandra
Solache, SVP of R&D, Abcam, said: “Thank you very much
to the team at CiteAb for this award. I am passionate about
promoting the importance of reagent quality across the life science
sector. It is an honor to receive this award and I would like to
share it with the many people across the industry that I have had
the pleasure and privilege to collaborate with throughout my
career. I would like to acknowledge my colleagues at Abcam for
their relentless efforts in placing the customer at the heart of
all we do and the Company’s long-term commitment to raising
industry standards.”
As a seasoned R&D scientist, Dr Alejandra
Solache has pioneered the development and adoption of sustainable,
consistent antibodies with the goal of addressing the
reproducibility crisis in the life sciences industry. She has
focused on identifying and removing variables in the antibody
development process. At Abcam, she successfully implemented a move
to large scale in-house production of recombinant reagents,
delivering over 20,000 novel recombinant monoclonal antibodies to
date. Critical to this, she established comprehensive validation
programs to ensure specificity, sensitivity and overall
performance, including the use of gold standard CRISPR gene-edited
knockout (KO) cell lines that has created an industry-leading
portfolio of over 3,000 KO validated antibodies.
Alejandra participates in many sector
initiatives with academic and industry thought leaders and was the
driving force behind Abcam’s first ‘Reproducible Science Week’
conference. She actively champions the need for researchers to
fully validate their own reagents to further address the issue of
poor experimental reproducibility.
Dr Andrew Chalmers, founder of CiteAb,
said: “I wish to offer my personal congratulations to Dr
Alejandra Solache on winning the CiteAb Award for Significant
Individual Impact. Anyone who has met her will understand why she
has won this award, she has such drive and passion for improving
research antibody quality and has championed the use of recombinant
antibodies and improved validation across the sector. Her efforts
have helped to ensure antibodies are fit to support biomedical
research and ultimately the patients receiving treatment. I wish
her continued success in her.”
In addition, Abcam received the ‘Antibody
Supplier Succeeding in Cardiovascular Research’ award, reflecting
its commitment to this crucial area of research. The team focuses
on emerging areas of interest, such as understanding the links
between cardiovascular events and the development of
neuropathologies and how this supports better diagnostics and
enhanced treatment options.
Notes to Editors
About Abcam plc
As a global life sciences company, Abcam
identifies, develops, and distributes high-quality biological
reagents and tools that are crucial to research, drug discovery and
diagnostics. Working across the industry, the Company supports life
scientists to achieve their mission, faster.
Abcam partners with life science organizations
to co-create novel binders for use in drug discovery, in vitro
diagnostics and therapeutics, driven by the Company's proprietary
discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays,
Abcam is helping advance the global understanding of biology and
causes of disease, which enables new treatments and improved
health. The Company's pioneering data-sharing approach gives
scientists increased confidence in their results by providing
validation, user comments and peer-reviewed citations for its
110,000 products.
With 13 sites globally, many of Abcam's
1,500-strong team are located in the world's leading life science
research hubs, complementing a global network of services and
support.
To find out more, please
visit www.abcam.com and www.abcamplc.com.
For media queries, contact:
Dr Lynne Trowbridge
VP External Communications
T: +44 (0)7815 167026
E: external.comms@abcam.com
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Aug 2024 to Sep 2024
AmerisourceBergen (NYSE:ABC)
Historical Stock Chart
From Sep 2023 to Sep 2024